IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CARLO STELLA, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.049
NA - Nord America 6.051
AS - Asia 4.668
SA - Sud America 673
AF - Africa 148
OC - Oceania 63
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.655
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.870
GB - Regno Unito 2.837
CN - Cina 1.771
IT - Italia 1.483
SG - Singapore 1.104
DE - Germania 1.001
SE - Svezia 814
RU - Federazione Russa 535
HK - Hong Kong 435
BR - Brasile 432
IN - India 287
TR - Turchia 281
UA - Ucraina 274
IE - Irlanda 201
KR - Corea 176
NL - Olanda 175
FR - Francia 170
JP - Giappone 157
FI - Finlandia 148
ES - Italia 127
VN - Vietnam 108
CA - Canada 106
AR - Argentina 92
EU - Europa 83
CO - Colombia 72
ID - Indonesia 61
MX - Messico 54
PL - Polonia 46
AU - Australia 42
BE - Belgio 41
TH - Thailandia 41
TW - Taiwan 35
CI - Costa d'Avorio 31
ZA - Sudafrica 30
BD - Bangladesh 28
CH - Svizzera 28
CZ - Repubblica Ceca 27
IL - Israele 26
IQ - Iraq 22
DK - Danimarca 21
EG - Egitto 21
PK - Pakistan 21
NZ - Nuova Zelanda 20
GR - Grecia 19
RO - Romania 19
AT - Austria 18
MA - Marocco 17
SA - Arabia Saudita 17
CL - Cile 16
EC - Ecuador 15
IR - Iran 15
KE - Kenya 15
PE - Perù 14
VE - Venezuela 13
HR - Croazia 11
LB - Libano 11
PT - Portogallo 11
UZ - Uzbekistan 11
JO - Giordania 10
UY - Uruguay 10
BG - Bulgaria 9
PH - Filippine 9
SK - Slovacchia (Repubblica Slovacca) 8
DZ - Algeria 7
ET - Etiopia 7
MY - Malesia 7
AZ - Azerbaigian 5
CR - Costa Rica 5
NG - Nigeria 5
NO - Norvegia 5
PY - Paraguay 5
BO - Bolivia 4
PS - Palestinian Territory 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HU - Ungheria 3
JM - Giamaica 3
LT - Lituania 3
OM - Oman 3
PA - Panama 3
RS - Serbia 3
SI - Slovenia 3
AM - Armenia 2
BY - Bielorussia 2
CY - Cipro 2
GH - Ghana 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MN - Mongolia 2
YT - Mayotte 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AW - Aruba 1
BN - Brunei Darussalam 1
BW - Botswana 1
GA - Gabon 1
Totale 19.717
Salva come PNG Salva come JPEG
Città #
Southend 2.563
Singapore 576
Ashburn 533
Frankfurt am Main 517
Milan 495
Seattle 456
Chandler 414
Hong Kong 402
Beijing 342
Wilmington 324
Princeton 261
Fairfield 219
Jacksonville 213
Dallas 211
Dublin 198
Council Bluffs 155
Nanjing 150
Woodbridge 150
Redwood City 148
Houston 138
Ann Arbor 124
Bengaluru 121
Los Angeles 112
Dearborn 108
Redmond 103
Shanghai 98
Guangzhou 96
Columbus 90
Mountain View 89
Serra 88
Des Moines 86
Santa Clara 86
Hefei 81
Cambridge 78
Buffalo 72
New York 70
Somerville 68
Sakarya 67
Moscow 63
Boardman 57
Bogotá 56
Hangzhou 55
Rome 55
Tianjin 53
Tokyo 52
Phoenix 51
The Dalles 50
Andover 47
São Paulo 46
Istanbul 44
Brescia 42
Jakarta 41
Nanchang 40
Jinan 39
Munich 35
Shenyang 35
Ho Chi Minh City 33
Buenos Aires 32
Abidjan 30
Cangzhou 29
Brussels 26
Hebei 26
Madrid 26
Toronto 25
Changsha 24
Hanover 24
Bologna 23
Chicago 23
Falls Church 23
Hanoi 23
London 23
Pisa 23
San Diego 23
Berlin 22
Seoul 22
Taipei 22
Helsinki 20
Jiaxing 20
Kunming 20
Sydney 20
Nuremberg 19
Zhengzhou 19
Ankara 18
Atlanta 18
Québec 18
Wuhan 18
Bangkok 17
Rio de Janeiro 17
Auburn Hills 16
Florence 16
Fuzhou 16
Philadelphia 16
Silver Spring 16
Washington 16
Cairo 15
Chengdu 14
Genova 14
Mumbai 14
Chongqing 13
Durham 13
Totale 11.868
Salva come PNG Salva come JPEG
Nome #
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study 2.128
FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress 687
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 600
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 383
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 265
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma 248
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection 244
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 241
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 225
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia 220
Targeting TRAIL Receptors with Genetically-Engineered CD34+ Hematopoietic Stem Cells 201
Ex vivo expansion of hematopoietic cells and their clinical use 201
Forced Expression of RDH10 Gene Retards Growth of HepG2 Cells 197
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 195
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 194
Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation 194
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 189
D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies 189
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 189
The anti-HLA-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing NOD/SCID mice 187
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 187
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 186
Skewed T cell differentiation in indolent non-Hodgkin's lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines 183
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 182
Amifostine (WR-2721) selective protection against melphalan genotoxicity 182
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 182
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature 181
Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells 180
Second mitochondria-derived activator of caspases mimetic compounds (Smac) enhance tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) pro-Apoptotic effect on human myeloid leukemia cell lines 175
Effect of Second Mitochondria-Derived Activator of Caspases (Smac) Mimetic Compounds on Leukemic Cell Lines 175
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 175
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 172
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 170
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 170
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed 169
Fattori di crescita emopoietici in oncologia 168
Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients 168
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis 167
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 166
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 166
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma 166
Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes 166
Antitumor activity of adenovirally transduced CD34+ cells expressing membrane-bound TRAIL 163
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY 163
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor : an algorithm for the pre-emptive use of plerixafor 161
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma 160
Synergistic in vitro effect of Second Mitochondria-derived Activator of Caspases mimetic compounds (Smac) and Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on human acute leukemia cell lines 159
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia 159
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 159
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 158
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 156
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 156
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 156
Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress™ Reagent 150
Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates 149
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies 148
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 145
Biology and clinical applications of marrow mesenchymal stem cells 143
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts 143
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 143
La sfida estrema : la plasticità delle cellule staminali 141
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells 140
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 139
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 139
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene 138
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors : mature results of an Italian randomized phase II study 138
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells 137
Methodological framework for radiomics applications in Hodgkin’s lymphoma 136
Cellule staminali emopoietiche 135
Section Editor per Ematologia Sperimentale di Annals of Hematology 131
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders 130
Membro del Comitato Editoriale di Stem cells 126
Trapianto di cellule staminali mesenchimali : razionale e prospettive 124
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers 124
Long-term lymphoma survivors following high-dose chemotherapy and autograft : evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir 123
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 123
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli 123
Membro del Comitato Editoriale di Recent patents on anti-cancer drug discovery 118
Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor 118
Radioimmunotherapy and secondary leukemia : a case report 117
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 117
Bone Marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide 117
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 115
Counterflow centrifugal elutriation: present and future 115
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia : evidence for premature aging of the myeloid compartment 115
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation 115
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells 111
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target 109
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells 105
Comparative assessment of telomere length before and after hematopoietic SCT : role of grafted cells in determining post-transplant telomere status 104
Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes 103
Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM 103
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma 101
The role of inflammation in lymphoma 100
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death 98
Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma 98
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma : a single institution experience 97
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide 97
Membro del Comitato Editoriale di Current stem cell research & therapy 96
The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia 95
Totale 18.495
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.810
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.810
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.383 0 0 0 0 0 171 150 104 244 211 395 108
2021/20221.576 185 77 74 118 88 122 118 95 112 152 108 327
2022/20231.905 247 190 150 201 205 364 78 132 167 34 83 54
2023/20241.520 54 113 94 88 291 86 126 115 63 95 166 229
2024/20252.904 176 330 97 296 164 96 123 328 198 207 274 615
2025/20262.584 548 325 593 483 551 84 0 0 0 0 0 0
Totale 20.598